Systemic therapy escalation after stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer

Cancer today [Internet]. [cited 2021 Sep 28]. Available from: http://gco.iarc.fr/today/home. Kelly, 2018, Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States, Eur. Urol. Focus, 4, 121, 10.1016/j.euf.2017.10.014 Huggins, 2002, Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, J. Urol., 167, 948, 10.1016/S0022-5347(02)80307-X Denmeade, 2002, A history of prostate cancer treatment, Nat. Rev. Cancer, 2, 389, 10.1038/nrc801 Cornford, 2021, EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer, Eur. Urol., 79, 263, 10.1016/j.eururo.2020.09.046 Fizazi, 2019, Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet Oncol., 20, 686, 10.1016/S1470-2045(19)30082-8 Schaeffer, 2021, NCCN guidelines insights: Prostate cancer, version 1.2021, J. Natl. Compr. Canc. Netw., 19, 134, 10.6004/jnccn.2021.0008 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: Long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J. Clin. Oncol., 36, 1080, 10.1200/JCO.2017.75.3657 James, 2017, Abiraterone for prostate cancer not previously treated with hormone therapy, N. Engl. J. Med., 377, 338, 10.1056/NEJMoa1702900 Ryan, 2015, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, Lancet Oncol., 16, 152, 10.1016/S1470-2045(14)71205-7 Magnan, 2015, Intermittent vs continuous androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis, JAMA Oncol., 1, 1261, 10.1001/jamaoncol.2015.2895 Hussain, 2013, Intermittent versus continuous androgen deprivation in prostate cancer, N. Engl. J. Med., 368, 1314, 10.1056/NEJMoa1212299 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial, J. Clin. Oncol., 36, 446, 10.1200/JCO.2017.75.4853 Siva, 2018, Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: A prospective clinical trial, Eur. Urol., 74, 455, 10.1016/j.eururo.2018.06.004 Decaestecker, 2014, Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence, Radiat. Oncol., 9, 10.1186/1748-717X-9-135 Bowden, 2020, Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial, Int. J. Cancer, 146, 161, 10.1002/ijc.32509 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial, JAMA Oncol., 6, 650, 10.1001/jamaoncol.2020.0147 Gravis, 2013, Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial, Lancet Oncol., 14, 149, 10.1016/S1470-2045(12)70560-0 Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM, et al. Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clin Genitourin Cancer. 2017 Aug;15(4):e623–32. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Apr 6;e230161.